Treatment of ARDS With Sivelestat Sodium (NCT04909697) | Clinical Trial Compass
CompletedPhase 4
Treatment of ARDS With Sivelestat Sodium
China324 participantsStarted 2022-04-18
Plain-language summary
Neutrophil elastase (NE) released by neutrophils play an important role in inflammatory cascade and lung tissue injury of ARDS.Inhibition of NE is expected to prevent the pathophysiological process of ARDS and alleviate lung injury. Siverestat sodium is a specific inhibitor of NE, which has been proved by basic and observational clinical studies to be effective in alleviating lung injury of ARDS, but there is a lack of prospective multi-center randomized controlled clinical trials.Therefore, this study was intended to evaluate the efficacy of sivelestat sodium in the treatment of ARDS patients with SIRS in a multicenter randomized controlled clinical trial
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females \> 18 years old and \<75 years old (non-pregnant, non-lactating females).
✓. Patients fulfilled the Berlin diagnostic criteria of acute respiratory distress syndrome, with a arterial oxygen partial pressure (PaO2) to fraction of inspired oxygen (FiO2) between 150 mmHg and 300 mmHg.
✓. Signed written informed consent has been obtained
Exclusion criteria
✕. History of chronic respiratory disease
✕. Single cardiogenic pulmonary edema
✕. Apach2 score ≥21 points
✕. Complicated with end-stage disease, or poor prognosis judged by the clinical doctor in charge
✕. ARDS course\>3 days
✕. Agranulocytosis or receiving immunosuppressive agents or high doses of corticosteroids (methylprednisolone\>40mg/day)